<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415374</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1314</org_study_id>
    <nct_id>NCT02415374</nct_id>
  </id_info>
  <brief_title>Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical</brief_title>
  <official_title>Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine whether orally ingested oat avenanthramides (AVA) in&#xD;
      oat flour cookies are bioavailable in humans by measuring plasma and urine concentrations of&#xD;
      AVAs and their potential metabolites after ingestion. The blood and urine concentrations will&#xD;
      be quantified at several different time points after the oat flour cookies are consumed to&#xD;
      characterize the &quot;concentration-time profile&quot;.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2015</start_date>
  <completion_date type="Actual">July 15, 2015</completion_date>
  <primary_completion_date type="Actual">July 15, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iAUC for each AVA</measure>
    <time_frame>0-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for each AVA</measure>
    <time_frame>0-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for each AVA</measure>
    <time_frame>0-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 for each AVA</measure>
    <time_frame>0-10 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Bioavailability</condition>
  <condition>Metabolism</condition>
  <condition>Avenanthramides</condition>
  <arm_group>
    <arm_group_label>Low-AVA oat flour cookies</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three low-AVA oat flour cookies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-AVA oat flour cookies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three high-AVA cookies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avenanthramides</intervention_name>
    <description>AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).</description>
    <arm_group_label>High-AVA oat flour cookies</arm_group_label>
    <arm_group_label>Low-AVA oat flour cookies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female non-obese subjects (18kg/M2&lt;BMI&lt;28kg/M2)&#xD;
&#xD;
          -  Age 20-45 years)&#xD;
&#xD;
          -  Sign an informed consent form approved by UMN-IRB&#xD;
&#xD;
          -  Willing to avoid oat consumption and rigorous physical activity the day prior to and&#xD;
             through test, and consume a low-flavonoid diet for 1 week prior to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of GI conditions that interfere with absorption;&#xD;
&#xD;
          -  Clinically significant endocrine, cardiovascular, pulmonary, renal, hepatic,&#xD;
             pancreatic, biliary or neurologic disorders;&#xD;
&#xD;
          -  Major trauma or surgery within 3 months of visit;&#xD;
&#xD;
          -  Cancer in the prior 2 years;&#xD;
&#xD;
          -  Allergic to oat products;&#xD;
&#xD;
          -  Women who are pregnant or lactating;&#xD;
&#xD;
          -  Smoking;&#xD;
&#xD;
          -  Drinking alcohol &gt;5 drinks/week;&#xD;
&#xD;
          -  Using nutraceuticals;&#xD;
&#xD;
          -  Blood pressure medication;&#xD;
&#xD;
          -  NSAID (&gt;800 mg ibuprofen/week);&#xD;
&#xD;
          -  Vitamin supplementation;&#xD;
&#xD;
          -  Anticoagulants or hypoglycemic drugs;&#xD;
&#xD;
          -  Oat products consumption the day before the test;&#xD;
&#xD;
          -  Rigorous physical activity the day before the test;&#xD;
&#xD;
          -  Consumption of a high-flavonoid diet in the week prior to the test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Li Ji, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Kinesiology (Cooke Hall), 1906 University Ave. SE, Minneapolis, MN 55455</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

